CPT 69806, in plain terms, covers Exploration of the endolymphatic sac through the mastoid with placement of a shunt to drain the inner ear fluid. CPT 69806 is referenced in 6 tracked payer policy changes from UnitedHealthcare and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 69806 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 69806 on AAPC
UnitedHealthcare is removing a long list of CPT codes from the applicable-code list of its Outpatient Surgical Procedures site-of-service policy for Exchange plans, and it is also removing the link to the Manipulation Under Anesthesia policy. The change takes effect December 1, 2026. The source does not state a new billing requirement for the removed codes.
Effective December 1, 2026, UMR removes more than 500 CPT codes from its Outpatient Surgical Procedures - Site of Service medical policy for commercial plans, and it drops a reference link to the Manipulation Under Anesthesia policy. For those codes, UMR's site-of-service policy no longer applies, so the practice should update its internal UMR site-of-service and prior authorization lists before that date.
Effective December 1, 2026, UnitedHealthcare removes more than 500 CPT codes from its Outpatient Surgical Procedures - Site of Service medical policy for commercial plans, and it drops a reference link to the Manipulation Under Anesthesia policy. For those codes, the site-of-service policy no longer applies under this UnitedHealthcare commercial policy, so the practice should update its internal site-of-service and prior authorization lists before that date.
Aetna considers dehydration testing with glycerol, urea, or other osmotic diuretics medically necessary to verify suspected endolymphatic hydrops (Meniere's disease) only in members with atypical presentations of the disease, and considers it experimental, investigational, or unproven for other indications. Aetna considers the following experimental, investigational, or unproven: endolymphatic sac immunohistochemistry of aquaporin-2, V2R, NKCC2 and TRPV4; genetic testing of KCNE1, KCNE3, SIK1, SLC8A1 and SLC26A4 for this diagnosis; intravenous gadolinium inner ear MRI; multi-frequency tympanometry; testing for antibodies against inner ear antigens; vestibular evoked myogenic potential (VEMP) testing for diagnosis and for monitoring disease progression; and the video head impulse test. The policy lists CPT codes 81406, 92517, 92518, 92519, 92550, 92567 and 92584 and HCPCS code A9579 as not covered for the indications listed, and ICD-10 codes for Meniere's disease, related vertigo, labyrinthitis, gait abnormalities and dizziness are covered if selection criteria are met.
Aetna considers these surgical interventions medically necessary for chronic refractory Meniere's disease: endolymphatic mastoid shunt, endolymphatic sac decompression or drainage, lateral semi-circular canal plugging, perilymphatic fistula patching, sacculotomy, tympanostomy tube insertion, vestibular nerve decompression, vestibular neurectomy or neurotomy, intra-tympanic corticosteroid injections or perfusions, cochleosacculotomy, intra-tympanic gentamicin, labyrinthectomy, translabyrinthine vestibular neurectomy and vestibulocochlear neurectomy. The policy also covers middle fossa craniotomy and trans-mastoid canal plugging for superior semicircular canal dehiscence when audiometry and computed tomography confirm the diagnosis, and intra-tympanic or trans-tympanic dexamethasone injection for sudden sensorineural hearing loss in members who failed conservative treatment including oral steroids or who have a medical condition that prohibits oral steroids. Aetna considers tenotomy of the stapedius and tensor tympani muscles, triple semi-circular canal plugging, positive pressure therapy for improving outcomes of endolymphatic sac surgery, cochleostomy with neurovascular transplant, intra-tympanic dexamethasone thermo-sensitive gel, and simultaneous labyrinthectomy with cochlear implantation for bilateral Meniere's disease experimental, investigational or unproven because their effectiveness has not been established.
Aetna considers dehydration testing with glycerol, urea, or other osmotic diuretics medically necessary to verify suspected endolymphatic hydrops (Meniere's disease) only in members with atypical presentations, and considers it experimental, investigational, or unproven for other indications. The policy also lists as experimental, investigational, or unproven: endolymphatic sac immunohistochemistry, genetic testing of KCNE1, KCNE3, SIK1, SLC8A1, and SLC26A4 for diagnosis, intravenous gadolinium inner ear MRI, multi-frequency tympanometry, testing for antibodies against inner ear antigens, VEMP for diagnosis and for monitoring disease progression, and the video head impulse test.
Watch 69806
Get one email when a payer policy names 69806, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 69806
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 69806 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.